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Effector memory CD41 T cells are
associated with cognitive performance in a
senior population
ABSTRACT
Objective: Immunosenescence and cognitive decline are common markers of the aging process.
Taking into consideration the heterogeneity observed in aging processes and the recently
described link between lymphocytes and cognition, we herein explored the possibility of an asso-
ciation between alterations in lymphocytic populations and cognitive performance.
Methods: In a cohort of cognitively healthy adults (n 5 114), previously characterized by diverse
neurocognitive/psychological performance patterns, detailed peripheral blood immunophenotyping
of both the innate and adaptive immune systems was performed by flow cytometry.
Results: Better cognitive performance was associated with lower numbers of effector memory
CD41 T cells and higher numbers of naive CD81 T cells and B cells. Furthermore, effector memory
CD41 T cells were found to be predictors of general and executive function and memory, even
when factors known to influence cognitive performance in older individuals (e.g., age, sex, edu-
cation, and mood) were taken into account.
Conclusions: This is the first study in humans associating specific phenotypes of the immune sys-
tem with distinct cognitive performance in healthy aging. Neurol Neuroimmunol Neuroinflamm
2015;2:e54; doi: 10.1212/NXI.0000000000000054
GLOSSARY
CM 5 central memory; CMV 5 cytomegalovirus; EM 5 effector memory; GDS 5 mood; GENEXEC 5 general and executive
function; LD 5 late differentiated; MEM 5 memory; Treg 5 regulatory T cell.
The identification of factors contributing to healthy aging is increasingly relevant in modern soci-
eties in order to define strategies to sustain and improve quality of life for older individuals. Immu-
nosenescence and cognitive decline are common changes accompanying aging, but their potential
interaction is far from being understood. In fact, the interaction between cognition and parameters
of the immune system has been explored mostly in the last decade, and largely through studies using
animal models.1–6 The current view is that the immune system plays a modulatory role in brain
function, including in cognitive abilities and neurogenesis,7,8 which supports the notion that
throughout life the brain is not “immune privileged” but rather “enjoys the privilege” of
immune-dependent maintenance. So far, it is established that (1) severe combined immune defi-
cient mice, which lack B and T cells, and nude mice, which are devoid of T cells, present a
significant impairment in hippocampal-dependent spatial learning and memory,3,9,10 and, impor-
tantly, these cognitive deficits are reversed by reconstituting the mouse immune system with T
cells3,9,10 but not with other immune cells10; (2) CD41 T cell–depleted mice present impaired
performance in reversal learning in the Morris water maze4; and (3) acute suppression of T cells by
immunosuppressive drugs currently used in clinical trials or in disease treatment is sufficient to cause
cognitive deficits in adult wild-type mice.1,3,10 In addition, very recent studies revealed that
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bloodborne factors from old mice are able to
impair spatial learning and memory as well as
neurogenesis and synaptic plasticity in young
animals.11 In contrast, blood from young ani-
mals is able to reverse age-related impair-
ments in cognitive function and synaptic
plasticity.12 While the precise bloodborne
factors influencing cognition remain to be
elucidated, they may relate to immune cells
and/or immune mediators.
Taking into consideration the data available
from animal studies and recognizing that both
age-associated cognitive decline and modifica-
tions on the immune cells vary greatly between
individuals,13,14 we hypothesized that there is
an association between age-associated alterations
in leukocytes and cognitive performance in
healthy aging individuals. To test this hypothe-
sis, we explored the association of the immune
system cells profile and the cognitive phenotype
in a well-characterized cohort of senior individ-
uals with distinct cognitive performances.
METHODS Participant characterization. The 114 par-
ticipants enrolled were selected from a cohort of 1,051
individuals, as representative of good and poor cognitive
performers based on neurocognitive/psychological per-
formance patterns.15,16 The participants from the initial
cohort are senior community-dwelling individuals living
in theMinho region of Portugal and are representative of
the country’s population in terms of age distribution,
sex, and school years. Participants who were unable to
attend the clinical and neuropsychological sessions, were
diagnosed with dementia and/or unable to understand
informed consent, or who had disorders of the central
nervous system or overt thyroid pathology, were
excluded from the larger cohort. The cohort was
established in accordance with the principles
expressed in the Declaration of Helsinki, and the
work was approved by the Portuguese national ethical
committee (Comissão Nacional de Protecção de Dados)
and by local ethics review boards. All the participants
gave voluntary informed written consent.
A team of trained psychologists assessed the cogni-
tive and mood profile of the participants as described in
Santos et al.16 Briefly, the cognitive profile was estab-
lished using a battery of neurocognitive and psycholog-
ical tests selected to evaluate short-term verbal memory,
verbal working memory, response inhibition/cognitive
flexibility, verbal fluency, multiple trial verbal learning
and memory, high-level information processing speed,
global cognitive status, and mood. Using a principal
component analysis, the neurocognitive/psychological
test variables were grouped into 3 dimensions: memory
(MEM), general and executive function (GENEXEC),
and mood (GDS) (for details see Santos et al.16). The
cognitive groups were classified as good and poor per-
formers following cluster analysis. All the statistical
analysis of the cognitive evaluation and individual
clustering followed the method in our previous publi-
cation.16 Descriptive information regarding age, sex,
school years, and scores for GDS, MEM, and
GENEXEC for all participants and for the good and
poor cognitive performance groups is described in table
e-1 at Neurology.org/nn.
While the full characterization of the acquired
immune system was performed for all 114 individu-
als, the innate immune system was analyzed for only
79 individuals (table e-2). The presence of anti-
cytomegalovirus (CMV) immunoglobulin G was
determined, and only 7 of the 114 participants were
considered nonimmune to CMV; no correlations
were observed between CMV antibody titers and
the cognitive performance of the participants. All par-
ticipants presented C-reactive protein levels below the
limit associated with active inflammation/infection
(10 mg/L).17 Information about anti-inflammatory/
immunomodulatory medication was collected at the
time of clinical interview; 18 of the participants were
receiving this type of therapy (information provided
in table e-1).
Flow cytometry analysis. Blood was collected to EDTA
blood collection tubes and processed for standard
hospital leukogram (Braga’s Hospital) and multipara-
metric flow cytometry analyses on the same day of
collection (see e-methods for details). Leukogram
analysis was conducted at the certified pathology lab-
oratory of Braga’s Hospital, following standard pro-
cedures. A code was assigned to each participant and
all the analyses were assessed blindly.
Statistical analysis. Data for MEM, GENEXEC, and
GDS were used in the analysis as z scores, as previ-
ously determined by Santos et al.16 To evaluate nor-
mal distribution of the variables, skewness and
kurtosis values were calculated and the approximate
normal distribution was defined for variables with
absolute values of skewness below 3 and of kurtosis
below 8.18 Levene test was used to evaluate equality of
variances.
To compare immune systems’ cell populations (cell
counts per mL of blood) between good and poor cog-
nitive performance groups (descriptive statistics of vari-
ables are presented in table e-2), an independent-sample
t test was performed for variables with normal distribu-
tion and aMann-WhitneyU test for variables with non-
normal distribution. p Values below 0.05 were consid-
ered significant, and to quantify the strength of the
differences, Cohen d was calculated as a measure of
2 Neurology: Neuroimmunology & Neuroinflammation
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
effect size (0.2 is considered a small effect size, 0.5 a
medium effect size, and 0.8 a large effect size).19
To correlate immune systems’ cell populations
(cell counts) with cognitive (MEM and GENEXEC)
dimensions, a Pearson correlation coefficient test was
performed for variables with normal distribution and a
Spearman rank correlation coefficient test for variables
with non-normal distribution. The coefficient of deter-
mination (R2) was calculated as a measure of effect size
(0.0196 is considered a small effect size, 0.1300 a
medium effect size, and 0.2600 a large effect size).19
Hierarchical regression analysis was performed
to compare different models to predict MEM or
GENEXEC dimensions (dependent variables) and
to test whether successive models fit better than
the previous ones. Variables with non-normal distribu-
tion and with tolerance values below 0.4 (to avoid mul-
ticollinearity between variables) were excluded from
the model. The statistical procedures were performed
in IBM SPSS Version 20 (IBM Corp, Armonk, NY).
RESULTS B cells, naive CD81 T cells, and effector
memory CD41 T-cell counts correlate with cognitive
performance.When characterizing the overall immune
system, no differences between good and poor cogni-
tive performers were observed in the leukogram cell
subpopulations (lymphocytes, monocytes, neutro-
phils, basophils, and eosinophils; figure e-1). A more
detailed flow cytometry analysis of the acquired
immune system cells revealed that, when compared
to poor performers, good cognitive performers pre-
sented significantly higher B-cell counts (figure 1A;
t(110)5 2.354, p5 0.020, d5 0.45). No differences
were seen between good and poor cognitive perform-
ers regarding total T-cell counts (figure 1B; t(110) 5
0.355, p 5 0.723) or the 2 main T-cell populations
(figure 1C; CD41 [t(110) 5 0.617, p 5 0.539] and
CD81 [t(110) 5 20.196, p 5 0.845]). The CD41
and CD81 T-cell compartments (naive, central mem-
ory [CM], effector memory [EM], and late differen-
tiated [LD]), whose proportion has been shown to
change with aging,20 displayed a distribution pattern
(figure 1, D and E) in accordance with the described
dynamics of these T-cell compartments in aging.20 It
is interesting that the poor cognitive performers pre-
sented higher numbers of EM CD41 T cells (figure
1D; t(110) 5 2 2.510, p 5 0.014, d 5 0.48), with
no differences in other CD41 T-cell compartments (fig-
ure 1D; naive t(109.9)5 1.770, p5 0.080; CM t(110)5
0.780, p 5 0.480; LD U(110) 5 1,545, z 5 20.108,
p5 0.919), and lower numbers of naive CD81 T cells
(figure 1E; t(93.75)5 2.600, p5 0.011, d5 0.54), with
no differences among the CD81 T-cell compartments
(figure 1E; CM U(110) 5 1,375, z 5 21.096, p 5
0.273; EM t(110) 5 20.774, p 5 0.440; LD t(110) 5
20.332, p 5 0.746).
No differences were noted in total regulatory T
cell (Treg) counts (figure 1F; t(106) 5 0.046, p 5
0.963) or in the Treg compartments (figure 1G; naive
Tregs t(106) 5 1.667, p 5 0.098; activated Tregs
t(106) 5 0.480, p 5 0.632; nonsuppressive Tregs
U(106) 5 1,387, z 5 20.361, p 5 0.718), possibly
indicating that this cell population is not associated
with cognitive performance.
There were no differences in the dendritic and nat-
ural killer cell counts (figure e-2).
EM CD41 T-cell numbers predict memory and executive
performance. Cognitive performance is known to relate
directly or indirectly to sex, age, mood and, particularly,
education.13,15,21–24 In addition, variations in the
immune system are associated with age and mood.20,25,26
Therefore, we next investigated whether these factors
influenced the differences observed in the immune sys-
tem between distinct cognitive performers. To do so,
hierarchical linear regressionmodels were used to predict
the GENEXEC and MEM dimension performances.
The adaptive immune system variables appeared to be
the most promising, so those that presented statistically
significant correlations with GENEXEC and MEM
(table e-3) were included in the regression model to
determine to what extent they were able to predict the
cognitive performance in both domains. The first
block of variables included age, sex, and school years,
which are known to strongly relate to cognitive
performance.13,15,16,21,24 The second block addressed
mood, which also affects cognitive function.15,16,22,23,27
The third (last) block included the immune system
variables (activated Tregs, naive CD41 T cells, CM
CD41 T cells, EM CD41 T cells, naive CD81 T cells
and B cells in the GENEXEC model; naive CD41 T
cells, EMCD41 T cells, naive CD81 T cells and B cells
in the MEM model). The hierarchical linear regression
analysis revealed that the first block predicted 38.6%
(adjusted R2) of the GENEXEC dimension variance
and that all variables were statistically significant predic-
tors (table 1; model 1). Adding the second block to the
model increased the prediction of GENEXEC signifi-
cantly 5.1% (R2 change), with the sex variable ceasing to
be a significant predictor (table 1; model 2). Finally, the
inclusion of the third block further increased the predic-
tive power by 7.5% (table 1; model 3). Overall, model
3, which comprises all the variables, predicted 47.9%
(adjusted R2) of the GENEXEC variance. Moreover, in
addition to age, mood, and school years, EM CD41 T
cells and B cells were statistically significant predictors of
GENEXEC. This means that even when considering
the variables previously known to affect cognitive func-
tion as predictors, the variables of the immune system
proved to be good predictors (although as expected with
lower impact [lower b]). Altogether these observations
indicate that better cognitive performers in the
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GENEXEC dimension are not just younger individuals
with higher education levels and better mood, as shown
previously, but also those with lower EM CD41 T-cell
counts and higher B-cell counts in the blood.
With respect to the MEM dimension, the hierar-
chical regression showed that the first block predicted
almost 20% (adjusted R2) of the MEM dimension
variance, with age and school years being statistically
Figure 1 Distinct cognitive performers present differences in the cell populations of the adaptive immune
system
The profile (cell counts per mL of blood) of good (black) and poor (red) cognitive performers with regard to B cells (A); T cells
(B); CD41 and CD81 T-cell subpopulations (C); CD41 and CD81T-cell compartments (D and E), subdivided as naive, central
memory (CM), effector memory (EM), and late differentiated (LD) T cells; CD41 regulatory T cells (Tregs) (F), subdivided as
naive Tregs, activated Tregs, and nonsuppressive Tregs (G). Each dot represents one individual and the line represents the
mean of the group. *p , 0.05.
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significant predictors (table 2; model 1). The addition
of the second block significantly increased the predic-
tive power 10.7% (R2 change), with mood being the
variable with the highest impact on MEM prediction
(table 2; model 2). The addition of the last block
raised statistical significance by 7.6% (table 2; model
3) for MEM. Following the GENEXEC findings, in
model 3 all variables comprehensively explained 33%
of the MEM dimension, in which, in addition to
mood, EM CD41 T cells were again statistically sig-
nificant predictors. The approach indicated that bet-
ter cognitive performers in memory function have
better mood scores and lower EM CD41 T-cell
counts.
It is also important to highlight that in this cohort
only 18 participants were receiving anti-inflammatory/
immunoodulatory treatment, and no differences were
detected in the cellular populations analyzed when
comparing individuals receiving treatment to those
not receiving treatment (data not shown). We also
included this factor in the hierarchical regression mod-
els as a factor to control, and anti-inflammatory/
immunomodulatory treatment showed no impact on
cognitive function or on the correlation between EM
CD41 T cells and cognitive performance (data not
shown).
DISCUSSION This study shows that better cognitive
performance in a healthy senior population is
associated with lower numbers of EM CD41 T cells,
higher numbers of naive CD81 T cells and higher
numbers of B cells. Furthermore, EM CD41 T cells
are predictors of GENEXEC and MEM, even when
factors known to influence cognitive performance
(e.g., age, sex, education and mood) are taken into
account.
The immune cell population strongly associated
with cognitive performance in our healthy senior
cohort is the EM CD41 T cells population. Higher
EM CD41 T-cell numbers negatively predict MEM
and GENEXEC performance. Of interest, other au-
thors reported that patients diagnosed with probable
Alzheimer disease and cognitive deficits according to
the Mini-Mental State Examination presented with
significantly lower levels of CD41 naive T cells
(CD45RA1) and an increase in the activated/naive
CD41 T-cell ratio (CD45RO1/CD45RA1) com-
pared with age-matched cognitively healthy individ-
uals.28 This suggests that pathologically related
cognitive deficits are associated with alterations in
the CD41 T-cell compartments.28 Of note, we also
observed more EM CD41 T cells in the poor cogni-
tive performers, even though the individuals enrolled
in our study presented no detectable pathologic cog-
nitive alteration. The link between CD41 T cells and
cognitive performance has been proposed based
on preclinical studies. In fact, systemic depletion
of CD41 T cells in mice significantly reduced
Table 1 Hierarchical linear regression models to predict GENEXEC
Model 1 Model 2 Model 3
B SE b t B SE b t B SE b t
Sexa 0.450 0.212 0.171 2.123* 0.263 0.213 0.100 1.237 0.339 0.208 0.129 1.628
Age 20.050 0.013 20.316 23.837*** 20.051 0.012 20.324 24.09*** 20.031 0.014 20.199 22.260*
School years 0.148 0.033 0.379 4.426*** 0.120 0.033 0.309 3.618*** 0.120 0.034 0.308 3.569***
zGDS 20.333 0.109 20.252 23.047** 20.287 0.106 20.217 22.693**
Activated Tregs 27.552 15.091 20.047 20.500
Naive CD41 T cells 20.071 0.630 20.010 20.113
CM CD41 T cells 0.080 0.678 0.011 0.118
EM CD41 T cells 21.803 0.779 20.169 22.315*
Naive CD81 T cells 5.967 3.689 0.150 1.618
B cells 2.655 1.16 0.189 2.289*
F (df1, df2) 22.557 (3,100)*** 20.64 (4,99)*** 10.468 (10,93)***
R2 0.404 0.455 0.530
Adjusted R2 0.386 0.433 0.479
R2 change 0.051 0.075
F change 9.283** 2.465*
Abbreviations: CM 5 central memory; EM 5 effector memory; Tregs 5 regulatory T cells.
*p , 0.05, **p , 0.01, ***p , 0.001.
a Reference category is male.
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hippocampal neurogenesis and impaired reversal
learning; such effects were not observed for CD81
T cells neither for B cells.4,29 Recent studies showed
that a substantial increase in CD41 T cells, but not in
CD81 T cells, was observed in the meninges of mice
that performed a cognitive task.1 Moreover, the re-
cruited cells were activated CD41 T cells (CD691;
CD251Foxp3-) producing IL-4 (Th2 phenotype) and
not IFN-g (Th1 phenotype),1 suggesting that the
cytokines produced by CD41 T cells may play a role
in cognition. In fact, a more proinflammatory profile
has been associated with cognitive impairments in
older individuals.30,31 Because EM CD41 T cells are
the major cytokine producers among T cells,32 the
association found in our population between higher
EM CD41 T cells and poor cognition may be related
to a more proinflammatory profile. Further studies
are needed to better understand the interplay between
the CD41 T-cell populations, their specific cytokine
production profile, and cognitive performance. This
study also identified an association between B-cell
counts and cognition (individuals with better cogni-
tive performance presented with higher B-cell
counts).
We next used hierarchical regression models to
investigate the impact of the immune system in both
the MEM and GENEXEC cognitive domains. The
analysis revealed that all the immune system variables
included in the models increased the predictive power
of both cognitive domains almost 8%. Because this
effect is in addition to the effect of other factors
known to explain cognitive performance in senior
populations, the effect of the immune system varia-
bles should be included when addressing cognitive
differences among older individuals. Regarding the
models used in this study, all variables explained
GENEXEC better than MEM. We previously dem-
onstrated that the predicted cognitive score (a “latent”
cognitive score calculated using structural equation
modeling based on 3 identified cognitive dimensions
[general and executive function, memory, and a
higher-level executive processing capacity] and 4 pre-
dictors [sex, age, school years, and GDS]) is more
strongly explained by GENEXEC than by MEM,
which is in agreement with the present observations.
Furthermore, in the structural equation model, the
included variables explained 62% of the variability of
the latent cognitive score,16 indicating that other
unknown factors are also of relevance. Based on the
current findings, the inclusion of immune system
parameters as predictors (mainly EM CD41 T cells
and/or B cells) can probably increase the explanation
of the variability of cognition observed among senior
individuals.
In summary, to the best of our knowledge, this is
the first study identifying a phenotype of the immune
system associated with poorer/better cognitive perfor-
mance in individuals with healthy cognitive aging. This
study is potentially limited by the relatively small num-
ber of participants; thus, the present findings must be
confirmed in other human cohorts fully characterized
for their neurocognitive/psychological performance
patterns in order to establish these “immunomarkers”
as predictors of cognitive performance in aging. In
Table 2 Hierarchical linear regression models to predict MEM
Model 1 Model 2 Model 3
B SE b t B SE b t B SE b t
Sexa 0.060 0.220 0.025 0.273 20.136 0.211 20.056 20.645 0.011 0.208 0.005 0.053
Age 20.030 0.013 20.205 22.210* 20.034 0.013 20.236 22.715** 20.025 0.013 20.171 21.857
School years 0.115 0.034 0.320 3.349*** 0.071 0.034 0.198 2.102* 0.065 0.033 0.179 1.964
zGDS 20.440 0.109 20.363 24.039*** 20.373 0.108 20.308 23.471***
Naive CD41 T cells 0.674 0.624 0.098 1.079
EM CD41 T cells 21.914 0.778 20.195 22.462*
Naive CD81 T cells 0.999 3.690 0.027 0.271
B cells 2.014 1.108 0.153 1.818
F (df1, df2) 8.69 (3,107)*** 11.528 (4,106)*** 7.783 (8,102)***
R2 0.196 0.303 0.379
Adjusted R2 0.173 0.277 0.330
R2 change 0.107 0.076
F change 16.310*** 3.117*
Abbreviations: CM 5 central memory; EM 5 effector memory; Tregs 5 regulatory T cells.
*p , 0.05, **p , 0.01, ***p , 0.001.
a Reference category is male.
6 Neurology: Neuroimmunology & Neuroinflammation
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
addition, prospective studies must follow on how the
immune system profile further relates to cognitive
decline.
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